Source Reference: Rabin AS, et al "Budesonide-formoterol metered-dose inhaler vs fluticasone-salmeterol dry-powder inhaler" JAMA Intern Med 2025; DOI: 10.1001/jamainternmed.2025.2299.

Switching from a metered dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition ...

Session ID: 2025-08-01:4c7a3985c3a55831994250c Player Element ID: vjs_video_3 ...

Journal reference: Woodcock, A., et al. (2022) Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis.

Key takeaways: A metered-dose inhaler was switched to a dry-powder inhaler in July 2021 in Veterans Affairs facilities. The transition went into action for nearly 75% of this study population.

The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 billion by 2034. The Industry is expected to surge at a CAGR of 3.70% from ...

The other single-inhaler on the market for COPD triple therapy, fluticasone-umeclidinium-vilanterol, is a dry-powder inhaler that does not contain hydrofluoroalkane-134a.

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization ...